Public Private Partnerships: Convene meetings to accelerate drug development (Milestone 14.B)
Convene meetings of the working groups for:
(i) Rapid Data Sharing and Analysis.
(ii) Enabling Bidirectional Translation in AD and ADRD drug development,
(iii) Eliminating IP barriers for Target Validation through clinical proof of concept. Each working group will formulate concrete steps needed to accelerate the timeframe of AD and ADRD drug development.
Recommendations developed on:
- (i) the creation of an open access, web-based resource that integrates complete, diverse multidimensional biological and chemical data that will be useful in advancing information on drug targets, including mechanistic information that will aid in the development of measures of target engagement (PD readouts);
- (ii) creation of computational tools for development of biological network models of AD, related dementias and normal aging;
- (iii) creation of tools that will foster development of bio network models that provide a predictive framework for using drugs in combination or singly;
- (iv) removing legal and IP barriers surrounding data sharing.
One or more partnerships established to accelerate key steps in AD drug development.
Summary of Key Accomplishments
In April 2013, the NIA convened a meeting on enabling partnerships for AD drug development that brought together more than 60 leaders from academia, the NIH, the Foundation for the NIH (FNIH) the FDA, other foundations, public advocacy groups, and the biotech and pharmaceutical industries. Breakout group discussions centered around new models of data sharing, translational science, and partnering as ways to accelerate AD research and drug development.
This information is current as of March 2022.
- Research Implementation Area
- Public Private Partnerships
- RFA-AG-13-013: Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimer's Disease (R01)
- RFA-AG-18-013: Continuation of the AMP-AD Target Discovery and Preclinical Validation Consortium (U01 Clinical Trial Optional) (reissue of RFA-AG-13-013)